Clinical effects of Bifidobacterium Longum Subsp. Infantis YLGB-1496 on children with respiratory symptoms.

IF 4 2区农林科学 Q2 NUTRITION & DIETETICS Frontiers in Nutrition Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI:10.3389/fnut.2025.1537610

Pin Li, Uma Mageswary, Adli Ali, Fahisham Taib, Thai Hau Koo, Azianey Yusof, Hua Jiang, Hanglian Lan, Weilian Hung, Min-Tze Liong, Yumei Zhang

{"title":"Clinical effects of Bifidobacterium Longum Subsp. Infantis YLGB-1496 on children with respiratory symptoms.","authors":"Pin Li, Uma Mageswary, Adli Ali, Fahisham Taib, Thai Hau Koo, Azianey Yusof, Hua Jiang, Hanglian Lan, Weilian Hung, Min-Tze Liong, Yumei Zhang","doi":"10.3389/fnut.2025.1537610","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to examine the effects of Bifidobacterium longum subsp. infantis YLGB-1496 (B. infantis YLGB-1496) on the frequency of respiratory illness symptoms and immunity profiles among toddlers.Methods: In this double-blind, randomized, placebo-controlled, 12-week intervention study, toddlers with at least 2 respiratory illness symptoms were randomly assigned into the probiotic (YLGB-1496) or placebo group at a 1:1 ratio. Follow-up examinations were conducted at baseline (week 0) and at weeks 6 and 12 of the intervention. The frequency of respiratory illness symptoms was assessed at these time points using validated questionnaires. Oral swabs and fecal samples were collected from participants at weeks 0, 6, and 12 to examine inflammatory cytokines.Results: Among the 120 toddlers initially included in the study, 115 completed the 12-week intervention (58 in the YLGB-1496 group and 57 in the placebo group). The risk of antibiotic use or clinical visits was significantly lower in the YLGB-1496 group than in the placebo group (antibiotic use odds ratio (OR) = 0.37 [0.369, 0.372]; clinical visit, OR = 0.743 [0.741, 0.744]), but these differences were nonsignificant after adjusting for other potential confounders (p > 0.05). The YLGB-1496 group presented a lower incidence of several respiratory symptoms than the placebo group, including fever (p < 0.001), cough (p < 0.001), sneezing (p = 0.012), nose block (p = 0.001), and runny nose (p < 0.001). The results also revealed that the salivary cortisol concentration was significantly lower in the YLGB-1496 group than in the placebo group (p = 0.026), but no effects on INF-γ, IL-1β, IL-13, IL-4, or IL-10 were detected.Conclusion: Bifidobacterium infantis YLGB-1496 may serve as a potential natural, nonpharmacological strategy for the safe management of respiratory tract issues in toddlers.Clinical trial registration: The trial was registered at ClinicalTrials.gov (identifier number NCT05794815).","PeriodicalId":12473,"journal":{"name":"Frontiers in Nutrition","volume":"12 ","pages":"1537610"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879798/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Nutrition","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fnut.2025.1537610","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to examine the effects of Bifidobacterium longum subsp. infantis YLGB-1496 (B. infantis YLGB-1496) on the frequency of respiratory illness symptoms and immunity profiles among toddlers.

Methods: In this double-blind, randomized, placebo-controlled, 12-week intervention study, toddlers with at least 2 respiratory illness symptoms were randomly assigned into the probiotic (YLGB-1496) or placebo group at a 1:1 ratio. Follow-up examinations were conducted at baseline (week 0) and at weeks 6 and 12 of the intervention. The frequency of respiratory illness symptoms was assessed at these time points using validated questionnaires. Oral swabs and fecal samples were collected from participants at weeks 0, 6, and 12 to examine inflammatory cytokines.

Results: Among the 120 toddlers initially included in the study, 115 completed the 12-week intervention (58 in the YLGB-1496 group and 57 in the placebo group). The risk of antibiotic use or clinical visits was significantly lower in the YLGB-1496 group than in the placebo group (antibiotic use odds ratio (OR) = 0.37 [0.369, 0.372]; clinical visit, OR = 0.743 [0.741, 0.744]), but these differences were nonsignificant after adjusting for other potential confounders (p > 0.05). The YLGB-1496 group presented a lower incidence of several respiratory symptoms than the placebo group, including fever (p < 0.001), cough (p < 0.001), sneezing (p = 0.012), nose block (p = 0.001), and runny nose (p < 0.001). The results also revealed that the salivary cortisol concentration was significantly lower in the YLGB-1496 group than in the placebo group (p = 0.026), but no effects on INF-γ, IL-1β, IL-13, IL-4, or IL-10 were detected.

Conclusion: Bifidobacterium infantis YLGB-1496 may serve as a potential natural, nonpharmacological strategy for the safe management of respiratory tract issues in toddlers.

Clinical trial registration: The trial was registered at ClinicalTrials.gov (identifier number NCT05794815).

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

长双歧杆菌亚种的临床疗效。YLGB-1496用于有呼吸道症状的儿童。

目的：研究长双歧杆菌亚种的作用。婴儿YLGB-1496 （B.婴儿YLGB-1496）对幼儿呼吸道疾病症状的频率和免疫状况的影响。方法：在这项双盲、随机、安慰剂对照、为期12周的干预研究中，至少有2种呼吸道疾病症状的幼儿按1:1的比例随机分为益生菌（YLGB-1496）组和安慰剂组。随访检查在基线（第0周）、干预的第6周和第12周进行。在这些时间点使用有效的问卷评估呼吸系统疾病症状的频率。在第0、6和12周收集参与者的口腔拭子和粪便样本，以检测炎症细胞因子。结果：在最初纳入研究的120名幼儿中，115名完成了为期12周的干预（YLGB-1496组58名，安慰剂组57名）。YLGB-1496组抗生素使用或临床就诊的风险显著低于安慰剂组(抗生素使用优势比（or） = 0.37 [0.369,0.372]；临床就诊，OR = 0.743[0.741,0.744])，但在调整其他潜在混杂因素后，这些差异不显著（p > 0.05）。ylgb - 1496组提出一些呼吸道症状的发生率低于安慰剂组,包括发烧(p p  = 0.012),鼻子阻塞(p = 0.001),和流鼻涕(p  = 0.026页),但没有影响正-γ,il - 1β,IL-13, il - 4、il - 10被检测到。结论：婴儿双歧杆菌YLGB-1496可能作为一种潜在的自然、非药物策略，用于婴幼儿呼吸道问题的安全管理。临床试验注册：该试验在ClinicalTrials.gov注册（识别码NCT05794815）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Nutrition Agricultural and Biological Sciences-Food Science

CiteScore

5.20

自引率

8.00%

发文量

2891

审稿时长

12 weeks

期刊介绍： No subject pertains more to human life than nutrition. The aim of Frontiers in Nutrition is to integrate major scientific disciplines in this vast field in order to address the most relevant and pertinent questions and developments. Our ambition is to create an integrated podium based on original research, clinical trials, and contemporary reviews to build a reputable knowledge forum in the domains of human health, dietary behaviors, agronomy & 21st century food science. Through the recognized open-access Frontiers platform we welcome manuscripts to our dedicated sections relating to different areas in the field of nutrition with a focus on human health. Specialty sections in Frontiers in Nutrition include, for example, Clinical Nutrition, Nutrition & Sustainable Diets, Nutrition and Food Science Technology, Nutrition Methodology, Sport & Exercise Nutrition, Food Chemistry, and Nutritional Immunology. Based on the publication of rigorous scientific research, we thrive to achieve a visible impact on the global nutrition agenda addressing the grand challenges of our time, including obesity, malnutrition, hunger, food waste, sustainability and consumer health.